Catalyst Crew Technologies Corp. (OTC: CCTC) announced that it has submitted a corporate action request to the Financial Industry Regulatory Authority (FINRA) seeking approval to change its corporate name to LataMed AI Corp. and its trading symbol to better reflect its transition toward artificial intelligence-enabled healthcare technology. The proposed changes were approved by the Company's Board of Directors and by written consent of the majority shareholder in accordance with Nevada law.
The name change is intended to align the Company's public identity with its strategic direction, which now focuses on healthcare analytics and technology-enabled healthcare services infrastructure, with an initial emphasis on Latin America. The Company noted that the proposed corporate action does not involve any reverse stock split, forward stock split, recapitalization, change to authorized capital, or other modification to its capital structure. The issued and outstanding share count will remain unchanged, and shareholders will not need to take any action.
Upon FINRA approval, the Company intends to file a Certificate of Amendment with the Nevada Secretary of State to effect the name change. The new name and symbol would become effective upon completion of the required filings and publication by FINRA on the Daily List. Dr. Kevin Rodan Levy, Chief Executive Officer, stated, “There is no change to the Company’s capital structure as part of this process. This proposed name change is intended to better align the Company’s public identity with its healthcare technology strategy and long-term market focus.”
The announcement is significant as it signals Catalyst Crew Technologies’ definitive pivot from its previous business direction to a focused healthcare AI strategy. The Company is actively developing scalable digital health solutions for emerging markets, including telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms. This strategic transition positions the Company to address the growing demand for modernized healthcare delivery systems across Latin America, a region with substantial unmet medical needs and increasing digital adoption.
Investors should note that no assurance can be given that FINRA will approve the proposed name change or the requested trading symbol. The Company is a development-stage enterprise and has not generated revenues from its newly announced business direction. For more information, visit https://catalystcrewai.com or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
The Company’s forward-looking statements involve risks and uncertainties, including its ability to successfully implement its business plan, secure financing, complete acquisitions, comply with regulatory requirements, and general market conditions. This press release is for informational purposes only and does not constitute an offer to sell securities.
